Study

ACTG175 was a randomized clinical trial to compare monotherapy with zidovudine or didanosine with combination therapy with zidovudine and didanosine or zidovudine and zalcitabine in adults infected with the human immunodeficiency virus type I whose CD4 T cell counts were between 200 and 500 per cubic millimeter.

Data

In R, the data is stored as ACTG175. The data originally come from the speff2trial package. However, for demonstration purposes, the analyses in this document are conducted from a copy of the dataset saved as a text file ACTG175.csv on http://therbootcamp.github.io. The analyses in this document are based on this text file.

Analyses

The full dataset contains data from 2139 patients. For each patient, there are 26 observations (i.e.; columns in the data). Table 1 shows the first 5 rows and first 4 columns of the full dataset:

Table 1: First 5 rows and 5 columns of the full ACTG175 dataset
pidnum age wtkg hemo homo
10056 48 90 0 0
10059 61 49 0 0
10089 45 88 0 1
10093 47 85 0 1
10124 43 67 0 1

One of the primary measures was the number of days until a major nevative event. Across all patients, the median number of days was 997. However, the results did differ between treatment arms. Summary statistics of the number of days, separated by each treatment arm, are presented in Table 2:

A plot showing the relationship between treatment arm and number of days until a major negative event are presented in Figure 2:

The correlation between CD4 T cell count at baseline and number of days until a major negative event was r = 0.19, p < .01.

Conclusions

Add your conclusions here! Include mini-chunks like min(ACTG175$days) which will return the value of 14